"What is more promising about this study was the utility in all of the cancers studied (
ovarian, cervical, breast, testicular, and lung), demonstrating that combining HDAC inhibitors with other therapies may be clinically useful in multiple types of malignancies."
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.